Floatz logo

Idx-1197

Homologous Recombination Repair Gene Mutation

Idience Co., Ltd.Small moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

12 Active assets in the Homologous Recombination Repair Gene Mutation cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
National Cancer Institute (NCI)
Phase 3B
Atezolizumab
National Cancer Institute (NCI)
Phase 3B
Eloxatin
National Cancer Institute (NCI)
Phase 3B
Niraparib
University of California, Davis
Phase 2CCC
Durvalumab
UNICANCER
Phase 2CCC

View all 15 →

Same molecule, other indications

Idx-1197 is also rated in:

Homologous Recombination DeficiencyDormant
CCC
Indicative ·
50 / 100
View asset →
neoplasmDormant
CC
Indicative ·
44 / 100
View asset →
Advanced Solid TumorsDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →